AndhraNews.net
Home » Business News » 2011 » February » February 16, 2011

BB Biotech nominates Dr. Erich Hunziker for election as director


February 16, 2011 - London

BB BIOTECH AG /BB Biotech nominates Dr. Erich Hunziker for election as directorProcessed and transmitted by Thomson Reuters.The issuer is solely responsible for the content of this announcement.

BB Biotech AG will ask shareholders at the general meeting on March 21, 2011 to elect Dr. Erich Hunziker, Deputy Head of the Corporate Executive Committee of the Roche Group, to the Board of Directors of BB Biotech as a new member. Erich Hunziker is the designated successor to the long-standing director Prof. Dr. David Baltimore, who will not stand for re-election at the next general meeting for reasons of age.

 

The Board of Directors of BB Biotech AG has nominated Erich Hunziker for election to the Board of Directors at the ordinary general meeting on March 21, 2011. Erich Hunziker is Chief Financial Officer and Deputy Head of the Corporate Executive Committee of the Roche Group. He will succeed Prof. Dr. David Baltimore, who announced at the end of October 2010 that, after serving on the Board of Directors for 17 years, he would be stepping down for reasons of age.

"I am very pleased that Erich Hunziker has accepted a seat on the Board of Directors of BB Biotech," commented Prof. Dr. Thomas Szucs, Chairman of the Board of Directors of BB Biotech. "His strong track record as the CFO of one of the world's largest pharmaceutical companies and his profound knowledge of the healthcare sector will be a major asset in the future development and success of BB Biotech. His professional background clearly broadens the knowledge and experience of the board's sitting directors."

Erich Hunziker (1953) was appointed Chief Financial Officer of Roche Group and a member of the Corporate Executive Committee in 2001 and was promoted to Deputy Head of the Corporate Executive Committee in 2005. Among his achievements at Roche, he is acknowledged for raising the bar with regard to investor relations and financial reporting in the healthcare sector. Thanks to his astute leadership and financial acumen, Roche earned high credit ratings which allowed it to finance the full acquisition of Genentech at favorable conditions. Erich Hunziker announced in mid-January that he would retire from Roche at the end of March 2011 and would focus on a number of board memberships.

Erich Hunziker earned a Ph.D. in Industrial Engineering from the Swiss Federal Institute of Technology in Zurich. He began his professional career at the Institute of Management & Industrial Engineering ETH, Zurich. From 1983 to 2001 he held various management positions at Corange, Boehringer Mannheim and the Diethelm Keller Group, ultimately serving as the company's CEO. Erich Hunziker is also a member of the Board of Directors of Holcim and Chugai Pharmaceuticals.

 

 

 

For further information:

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland
Thomas Egger, Tel. +41 44 267 67 09, teg@bellevue.ch
www.bbbiotech.com

 

 

Company profile

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector with CHF 1.2 bn in assets under management. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: BB BIOTECH AG via Thomson Reuters ONE

GlobeNewswire

Comment on this story

Share